Author

Ralph P. Robinson

ORCID 0000-0002-4066-5299Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Bioinformatics· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 1 Organism:human· 1 Approach:machine learning (classical)· 1 Organism:mouse· 1 Organism:non-human primate· 1 Assay:protein structure· 1 Approach:statistical model· 1

Frequent Co-Authors

Blake H. BalcombiD· 2 shared Bruce A. LefkeriD· 2 shared D. FearoniD· 2 shared Ed GriffeniD· 2 shared Haim Michael BarriD· 2 shared John D. ChoderaiD· 2 shared Noa Lahav· 2 shared A. Kenneth MacLeodiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioinformatics

Blake H. BalcombORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A Structure-Based Computational Pipeline for Broad-Spectrum Antiviral Discovery

Maria A. Castellanos, Alexander Matthew Payne, Jenke Scheen, Hugo MacDermott-Opeskin, Iván Pulido, Blake H. Balcomb, Ed Griffen, D. Fearon, Haim Michael Barr, Noa Lahav, David L. Cousins, Jessica Stacey, Ralph P. Robinson, Bruce A. Lefker, John D. Chodera

This paper introduces a computational pipeline for identifying broad-spectrum antivirals by analyzing viral sequences, predicting ligand poses, and scoring protein-ligand complexes, validated on SARS-CoV-2 and MERS-CoV datasets.

bioRxiv · Jul 29, 2025 · PreprintBioinformatics

Open-science discovery of DNDI-6510, a compound that addresses genotoxic and metabolic liabilities of the COVID Moonshot SARS-CoV-2 Mpro lead inhibitor

Ed Griffen, D. Fearon, Briana Lynn McGovern, L. Koekemoer, Blake H. Balcomb, Tamás Szommer, Gwendolyn Fate, Ralph P. Robinson, Bruce A. Lefker, Shirly Duberstein, Noa Lahav, Stéphanie Braillard, Laura Vangeel, Manon Laporte, Fabienne Burgat Charvillon, , Annette von Delft

This paper describes the optimization of a SARS-CoV-2 Mpro inhibitor to address genotoxic and metabolic liabilities, leading to improved in vivo efficacy and exposure.

bioRxiv · Jun 16, 2025 · PreprintPharmacology & Toxicology